Feb. 23 at 11:31 AM
$ABEO
They only need small number of treatments per month to become profitable .. There is enough demand ..
Revenue is forecasted to ramp up significantly to an average of
$112.09 million (low:
$79.84 million, high:
$140.3 million), which could support breakeven or better if costs are controlled as planned.
One analysis (from Riverwater Partners, October 2025) projects ~50 total patient treatments in 2026 to generate approximately
$140 million in revenue (at an estimated net price of ~
$2.8 million per treatment), with gross margins of 80-85%.
Reimbursement facilitation: A permanent HCPCS J-code (J3389 for topical administration, prademagene zamikeracel, per treatment) was assigned by CMS and became effective January 1, 2026. This streamlines billing, claims processing, and reimbursement for qualified treatment centers (QTCs) and hospitals, supporting broader adoption and patient access
